In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

The stock's fall snapped a five-day winning streak.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

A bounding pulse is when your heart beats strongly. You may feel your pulse in your neck, wrist, or foot. Here’s why it ...

Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

The event will pave the way for new commitments from First Ladies, ministers, and the Merck Foundation team to create more ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Find out more about six immunology companies that have recently raised impressive funds in the biotech industry.